基于红细胞CD38抗原遮蔽策略消除达雷妥尤单抗药物对IgG型抗体效价检测的影响

李璐 ,  王斌 ,  魏俊杰 ,  刘海云 ,  尹楚慧 ,  吴伟鑫 ,  张印则

中国输血杂志 ›› 2026, Vol. 39 ›› Issue (9) : 1269 -1272.

PDF (1522KB)
中国输血杂志 ›› 2026, Vol. 39 ›› Issue (9) : 1269 -1272. DOI: 10.13303/j.cjbt.issn.1004-549x.2026.09.015
论著

基于红细胞CD38抗原遮蔽策略消除达雷妥尤单抗药物对IgG型抗体效价检测的影响

作者信息 +

Elimination of daratumumab interference with IgG antibody titer detection based on the erythrocyte CD38 antigen masking strategy

Author information +
文章历史 +
PDF (1558K)

摘要

目的 通过消除达雷妥尤单抗(Daratumumab, DARA)对 IgG 型抗-A/ 抗-B 抗体效价检测的干扰,解决试验结果与理论不相符问题,得出准确可靠的试验结果。方法 对 IgG 型抗-A 效价检测结果为阳性的 A 型标本,经查确认近期 DARA 用药史,通过使用兔抗人 CD38 功能性单抗对试剂细胞进行预处理,对破坏 IgM 型抗体后的血浆,采用倍比稀释法,通过抗人球蛋白检测卡行 IgG 型抗-A/ 抗-B 效价检测。结果 该标本未经兔抗人 CD38 功能性单抗预处理,其 IgG 型抗-A 效价检测结果为 128;经兔抗人 CD38 功能性单抗预处理后,IgG 型抗-A 效价检测结果为阴性。结论 基于红细胞 CD38 抗原遮蔽策略,使用兔抗人 CD38 功能性单抗预处理红细胞,可消除 DARA 对 IgG 型抗体效价检测的干扰,为临床治疗提供精准的诊断依据与决策支持。

Abstract

Objective To eliminate the interference of daratumumab (DARA) in the titer determination of IgG antiA/ antiB antibodies, resolve the discrepancy between test results and theoretical expectations, and obtain accurate and reliable test results. Methods A group A blood sample with a positive IgG antiA titer result was confirmed to have a recent history of DARA administration. After removal of IgM antibodies from the plasma, IgG antiA/ antiB titers were determined using the antiglobulin test card with a serial twofold dilution method, following pretreatment of reagent red blood cells with a rabbit antihuman CD38 functional monoclonal antibody. Results Without pretreatment with the rabbit antihuman CD38 functional monoclonal antibody, the IgG antiA titer of the sample was 128. After pretreatment, the IgG antiA titer became negative. Conclusion Based on the red blood cell CD38 antigen masking strategy, pretreatment of red blood cells with a rabbit antihuman CD38 functional monoclonal antibody can eliminate the interference of DARA on the titer determination of IgG antibodies, thereby providing accurate diagnostic evidence and decision support for clinical treatment.

关键词

达雷妥尤单抗 / 抗体效价检测 / 间接抗人球蛋白试验 / CD38 功能性单抗

Key words

daratumumab(DARA) / antibody titer determination / indirect antiglobulin test (IAT) / CD38 functional monoclonal antibody

引用本文

引用格式 ▾
李璐,王斌,魏俊杰,刘海云,尹楚慧,吴伟鑫,张印则. 基于红细胞CD38抗原遮蔽策略消除达雷妥尤单抗药物对IgG型抗体效价检测的影响[J]. 中国输血杂志, 2026, 39(9): 1269-1272 DOI:10.13303/j.cjbt.issn.1004-549x.2026.09.015

登录浏览全文

4963

注册一个新账户 忘记密码

参考文献

[1]

CRYSANDT M, SOYSAL H, JENNES E, et al. Selective ABO immunoadsorption in hematopoietic stem cell transplantation with major ABO incompatibility[J].Eur J Haematol, 2021,107(3):324-332.

[2]

ARAUJO A B, SCHMALFUSS T, FURLAN J M, et al. The impact of infused red blood cell volume on major and bidirectional ABO-mismatched bone marrow transplantation[J].Cytotherapy, 2024,26(10):1179-1184.

[3]

姚灿,李晓,贾新燕,等. 应用达雷妥尤单抗治疗单克隆免疫球蛋白沉积病肾损害的探索[J].中华肾脏病杂志,2025,41(8):571-578.

[4]

YAO C, LI X, JIA X Y, et al. Exploration of the application of daratumumab in the treatment of monoclonal immunoglobulin deposition disease with renal injury[J].Chin J Nephrol,2025,41(8):571-578.

[5]

高帆,周玉兰,王诗轩,等. 含达雷妥尤单抗的联合方案治疗多发性骨髓瘤的疗效和安全性分析[J].中国实验血液学杂志,2025,33(3):810-815.

[6]

GAO F, ZHOU Y L, WANG S X, et al. The efficacy and safety of daratumumab-based combination therapy in multiple myeloma[J].J Exp Hematol,2025,33 (3): 810-815.

[7]

高帆,李菲. 达雷妥尤单抗在非多发性骨髓瘤疾病中的研究进展和应用[J].中国实验血液学杂志,2023,31(5):1574-1578.

[8]

GAO F, LI F. Research progress and application of daratumumab in nonmultiple myeloma[J].J Exp Hematol, 2023,31(5):1574-1578.

[9]

LOCKHART A, EASTERBROOK J, WILSON L, et al. Daratumumab interference with blood-compatibility testing after autologous stem cell transplantation[J].Transfus Med, 2023,33(1):92-93.

[10]

NEDUMCHERIL M T, DESIMONE R A, RACINE-BRZOSTEK S E, et al. Overcoming drug interference in transfusion testing:A spotlight on daratumumab[J].J Blood Med, 2021,12:327-336.

[11]

CHAMI B, OKUDA M, MOAYERI M, et al. Anti-CD38 monoclonal antibody interference with blood compatibility testing:Differentiating isatuximab and daratumumab via functional epitope mapping[J].Transfusion, 2022,62 (11):2334-2348.

[12]

MURPHY M F, RAJBHANDARY S, CARAYIANNIS S, et al. How do transfusion services manage patients taking therapies such as anti-CD38 and anti-CD47 known to interfere with red blood cell compatibility testing?[J].Transfusion, 2024,64(7):1217-1222.

[13]

ZHOU Y, CHEN L, JIANG T, et al. 2-Mercaptoethanol (2-ME)-based IATs or Polybrene method mitigates the interference of daratumumab on blood compatibility tests[J].Hematology, 2021,26(1):365-370.

[14]

CHAPUY C I, AGUAD M D, NICHOLSON R T, et al. International validation of a dithiothreitol (DTT)-based method to resolve the daratumumab interference with blood compatibility testing[J].Transfusion, 2016, 56 (12):2964-2972.

[15]

LANCMAN G, ARINSBURG S, JHANG J, et al. Blood transfusion management for patients treated with anti-CD38 monoclonal antibodies[J].Front Immunol, 2018, 9:2616.

[16]

HABICHT C P, RIDDERS M, GRUEGER D, et al. Mitigation of therapeutic anti-CD38 antibody interference with fab fragments: How well does it perform?[J].Transfusion, 2023,63(4):808-816.

[17]

SELLENG K, GEBICKA P D, THIELE T. F(ab ') 2 fragments to overcome daratumumab interference in transfusion tests[J].N Engl J Med, 2018,379(1):90-91.

[18]

HABICHT C P, SCHNEEWEISS C. Antigen masking indirect antiglobulin test can mitigate the interference of Mezagitamab, a novel anti-CD38 antibody, in serological pre-transfusion testing[J].Transfus Med, Published online April 9, 2025. DOI:10. 1111/ TME. 13139.

[19]

ZHANG L, ZHAGN Y, QI J, et al. A rabbit anti-human CD38 antibody for eliminating daratumumab and isatuximab interference in immunohematology testing[J]. Front Immunol, 2026,17:1726341.

[20]

张良子,徐华,李璐,等. 兔源抗人 CD38 多克隆抗体消除达雷妥尤单抗对间接抗球蛋白法干扰的研究与应用[J].中国实验血液学杂志, 2026, 34 (4): 1165-1173.

[21]

ZHANG L Z, XU H, LI L, et al. Study and application of rabbit anti-Human CD38 polyclonal antibodies in eliminating daratumumab interference in the indirect antiglobulin test[J].J Exp Hematol,2026,34(4):1165-1173.

基金资助

深圳市南山区卫生科技计划项目(NS2025008)

深圳市血液中心科研课题项目(SZBC202504)

AI Summary AI Mindmap
PDF (1522KB)

0

访问

0

被引

详细

导航
相关文章

AI思维导图

/

〈 〉